AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Krishnan and Dhakal discuss MajesTEC-1 trial findings on teclistamab for relapsed/refractory multiple myeloma, highlighting efficacy (63% ORR, 46.1% CR) and safety concerns, including infections and AEs. They suggest future treatment shifts towards fixed-duration therapy and individualized dosing based on patient response.

Janssen-Cilag International NV announces CHMP recommendation for DARZALEX subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem-cell transplant. Supported by Phase 3 PERSEUS study data, this aims to establish a new standard of care, enhancing progression-free survival.

Quad countries launch a cancer initiative in the Indo-Pacific, focusing on cervical cancer prevention, detection, and treatment. The initiative aims to improve health infrastructure, expand research collaborations, and support cancer care through various commitments from governments and non-government organizations.

FDA approves Sarclisa (isatuximab) in combination with VRd for newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant, based on IMROZ phase 3 study showing significant PFS improvement. This marks Sarclisa's third indication and first for newly diagnosed patients, reflecting Sanofi's commitment to addressing critical care gaps in multiple myeloma.

Sarclisa approved in the US as the first anti-CD38 therapy in combination with VRd for newly diagnosed multiple myeloma patients not eligible for transplant, significantly improving progression-free survival.

CAR T-cell therapy toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are common and range from mild to severe. CRS is managed with corticosteroids and tocilizumab, while ICANS requires supportive care and corticosteroids. Emerging treatments like anakinra and itacitinib show promise in managing these toxicities.

Sanofi's Sarclisa approved by FDA as first-line treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant, in combination with bortezomib, lenalidomide, and dexamethasone.

European Commission approves VYLOY™ (zolbetuximab) for first-line treatment of advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2 positive tumors, extending progression-free and overall survival in Phase 3 trials.

FDA approves isatuximab-irfc plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible NDMM, supported by phase 3 IMROZ trial showing significant PFS benefit with Isa-VRd vs VRd alone.

FDA approves Sarclisa, the first anti-CD38 therapy, in combination with VRd for newly diagnosed multiple myeloma patients not eligible for transplant, significantly reducing disease progression or death by 40%.